Where I see patients (1)
Selected research
-
The Irreversible FLT3 Inhibitor FF-10101 Is Active Against a Diversity of FLT3 Inhibitor Resistance Mechanisms.
Molecular cancer therapeutics
-
Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia.
Cancer discovery
-
High-throughput screening for small-molecule inhibitors of LARG-stimulated RhoA nucleotide binding via a novel fluorescence polarization assay.
Journal of biomolecular screening
Contact me
- Request appointment
- Refer a patient
- (415) 353-2421